Tilray's Aphria RX Receives First Cannabis Cultivation License Under Germany's New Cannabis Act
Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its Germany cannabis cultivation facility, Aphria RX GmbH ("Aphria RX"), has received the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act. The new cannabis cultivation license allows Aphria RX to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in Germany.